Abstract:
This was a case control study conducted at Khartoum hospital during the period from
April to October 2022, aimed to measure D-dimer, platelets count and indices, and platelet
to lymphocyte ratio among Sudanese patients of prostate cancer in Khartoum state. A total
of 100 subjects were involved in this study, 50 prostate cancer patients as cases and 50
healthy volunteers as control (1:1) matched age and sex. Data were collected using a prestructured
questionnaire filled by direct interview with participants. Venous blood (4.3 ml)
was collected from each participant and distributed in two containers, 2.5 ml EDTA
sample was analyzed by Sysmex automated hematology analyzer for measurement of
complete blood count and 1.8 ml in trisodium citrate containers for measuring D- dimer
level. Data were analyzed by statistical of package social science (SPSS), version 25. The
statistical analysis was performed by using independent t-test and chi-square test (A Pvalue
of < 0.05 was considered significant). Result showed that D-dimer level was
significantly increased in patients with prostate cancer compared with control group
(1.72μg/ml) and (0.18±0.07) with P-value (0.00), MPV, PDW, PLCR and PCT were
significantly higher in prostate cancer patients compared with control means (10.20±0.88
fl) vs. (8.06±0.81 fl), (11.81±2.06 fl) vs. (10.49±1.04fl), (26.61±7.15%) vs.
(14.64±5.17%) and (0.26±0.10%) vs. (0.19±0.04%) respectively, (P value = 0.00). There
was no significant difference between two groups in regard to platelets count, PLR (pvalue
>0.05). The study also showed that patients who received chemotherapy had higher
PDW (p-value 0.05).
In conclusion, patients with prostate cancer had higher plasma D-dimer level, MPV,
PDW, PCT and PLCR. PDW were higher in prostate cancer patients receiving
chemotherapy.
